Carl Zeiss Meditec’s re-rating journey should continue further
21/02/24 -"Despite our near-term estimates being slightly moderated due to the destocking of consumables and anticipated impact from volume-based procurement headwinds, our target price resets higher by c.4%, ..."
Pages
62
Language
English
Published on
21/02/24
You may also be interested by these reports :
14/07/26
Dräger delivered a strong set of Q2 2026 preliminary figures, with both revenue and earnings ahead of consensus. The guidance upgrade on the EBIT ...
10/07/26
Following Thermo Fisher’s unsuccessful bid in 2020, Qiagen gradually restructured its business, focusing on non-COVID growth avenues. However, in ...
10/07/26
Non Pharma Health stocks have long been suffering. The sector has lost 39% ytd, not helped by EssilorLuxottica’s -35% correction. EL’s connected ...
23/06/26
There’s an interesting paradox at the heart of Sartorius Stedim Biotech’s (SSB; ADD; France) investment case. Since our last push in February 2025, ...